Biogen News and Research

RSS
FDA approves Tysabri to treat Crohn's disease

FDA approves Tysabri to treat Crohn's disease

Renewed search for lupus treatments and cure

Renewed search for lupus treatments and cure

Rituximab reduces disease activity in multiple sclerosis

Rituximab reduces disease activity in multiple sclerosis

Lawmakers have proposed 'witch's brew' of biotech bills

Lawmakers have proposed 'witch's brew' of biotech bills

New discoveries about stem cells in leukemia, breast and colon cancer

New discoveries about stem cells in leukemia, breast and colon cancer

MS sufferers relieved as drug Tysabri goes back on the market

MS sufferers relieved as drug Tysabri goes back on the market

FDA approves resumed marketing of Tysabri

FDA approves resumed marketing of Tysabri

MS sufferers lobby for return of Tysabri

MS sufferers lobby for return of Tysabri

Extensive study of natalizumab

Extensive study of natalizumab

Trials on MS drug Tysabri renews hope for sufferers

Trials on MS drug Tysabri renews hope for sufferers

FDA approves Rituxan (Rituximab)

FDA approves Rituxan (Rituximab)

Withdrawn MS drug works for Crohn's sufferers

Withdrawn MS drug works for Crohn's sufferers

Multiple sclerosis drug Tysabri could be back on the market later in the year

Multiple sclerosis drug Tysabri could be back on the market later in the year

Radioimmunotherapy streamlines non-Hodgkin's lymphoma treatment

Radioimmunotherapy streamlines non-Hodgkin's lymphoma treatment

Increased scrutiny of new multiple sclerosis-fighting drugs after Tysabri withdrawal

Increased scrutiny of new multiple sclerosis-fighting drugs after Tysabri withdrawal

New MS drug withdrawn from the market

New MS drug withdrawn from the market

Australian biotech, Bionomics acquires central nervous system (CNS) business

Australian biotech, Bionomics acquires central nervous system (CNS) business

GlaxoSmithKline acquires full marketing and development rights for BEXXAR worldwide

GlaxoSmithKline acquires full marketing and development rights for BEXXAR worldwide

FDA approval of Tysabri, for the treatment of multiple sclerosis

FDA approval of Tysabri, for the treatment of multiple sclerosis

Results from study of Rituxan in rheumatoid arthritis show promise

Results from study of Rituxan in rheumatoid arthritis show promise